The role of interleukin (IL)-27 in the endogenous anti-tumour immune response and the use of an IL-27 agonist as a cancer therapeutic.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1044967

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Our data in mice suggest that immune cell signalling protein, interleukin (IL)-27, enhances anti-tumour immune responses and slows growth of mammary tumours and carcinogen induced sarcomas. This project aims to test how IL-27 promotes protective anti-tumour immune responses and to develop a modified IL-27 protein that will be tested as a cancer therapeutic in mice. This will be the first study to examine IL-27 function using physiological tumour models and may provide proof of concept for a new therapeutic strategy for some human cancers.

Funded Activity Details

Start Date: 01-01-2013

End Date: 01-01-2015

Funding Scheme: Project Grants

Funding Amount: $473,960.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

carcinogenesis | carcinogens | cytokine therapy | immunology | interleukins (IL) | mammary gland cancer | sarcoma | tumour immunology

Related Links